Paper28889792
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD and 32 others. N Engl J Med, 2017. Cited by 2,966 papers, by iCite.
Cite this record
ConductScience Library. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Papers, record 28889792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28889792
- Disease
- melanoma589 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Melanoma | Major topic |
| Skin Neoplasms | Major topic |
| Adult | |
| Aged | |
| Disease-Free Survival | |
| Double-Blind Method | |
| Humans | |
| Ipilimumab | |
| Kaplan-Meier Estimate | |
| Middle Aged | |
| Neoplasm Staging | |
| Nivolumab | |
| Survival Rate |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH |
Source NIH RePORTER
Trials6
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | Background | ClinicalTrials.gov | |
| NCT04165967 | Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma | Background | ClinicalTrials.gov | |
| NCT05235737 | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab | Background | ClinicalTrials.gov | |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | Background | ClinicalTrials.gov | |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma | Background | ClinicalTrials.gov |
Comments and corrections7
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 31442371 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab. | https://conductscience.org/library/papers/31442371 | PubMed |
| Comment in | 29265785 | Nivolumab and Ipilimumab in Advanced Melanoma. | https://conductscience.org/library/papers/29265785 | PubMed |
| Comment in | 29265786 | Nivolumab and Ipilimumab in Advanced Melanoma. | https://conductscience.org/library/papers/29265786 | PubMed |
| Comment in | 29360923 | First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. | https://conductscience.org/library/papers/29360923 | PubMed |
| Comment in | 29668089 | A new era of proactive melanoma therapy: hit hard, hit early. | https://conductscience.org/library/papers/29668089 | PubMed |
| Comment in | 29766492 | Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56. | https://conductscience.org/library/papers/29766492 | PubMed |
| Comment in | 36394225 | Immunotherapy Combinations Proliferating in Immuno-Oncology. | https://conductscience.org/library/papers/36394225 | PubMed |
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16579821 | Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. | J Eval Clin Pract | 2006 | https://conductscience.org/library/papers/16579821 | PubMed |
| 2 | 25891304 | Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25891304 | PubMed |
| 3 | 25667295 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25667295 | PubMed |
| 4 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 5 | 21639810 | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21639810 | PubMed |
| 6 | 27622997 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27622997 | PubMed |
| 7 | 28475671 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28475671 | PubMed |
| 8 | 25891173 | Pembrolizumab versus Ipilimumab in Advanced Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25891173 | PubMed |
| 9 | 26027431 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26027431 | PubMed |
| 10 | 10877287 | Time-dependent ROC curves for censored survival data and a diagnostic marker. | Biometrics | 2000 | https://conductscience.org/library/papers/10877287 | PubMed |
Cited by2,016
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,966 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979397 | Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell-Associated Neurotoxicity Syndrome. | J Brown Hosp Med | 2026 | https://conductscience.org/library/papers/42979397 | PubMed |
| 42964829 | Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42964829 | PubMed |
| 42964611 | Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42964611 | PubMed |
| 42964167 | An m5C-associated NSUN5-YBX1-CENPF programme marks melanoma cell states and immune features. | Front Immunol | 2026 | https://conductscience.org/library/papers/42964167 | PubMed |
| 42938860 | Reprogramming the Melanoma Tumor Microenvironment: From Cellular Crosstalk to Cellular Immunotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938860 | PubMed |
| 42934318 | Safety and efficacy of dual immune checkpoint inhibition for melanoma brain metastases and its comparison to ICI monotherapy: A systematic review and meta-analysis. | Neurosurg Rev | 2026 | https://conductscience.org/library/papers/42934318 | PubMed |
| 42927598 | Peripheral immune tolerance as a driver of tumor immune escape and therapy resistance. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42927598 | PubMed |
| 42920926 | Optimising cancer immunotherapy and emerging data supporting de-escalation strategies. | BMJ Oncol | 2026 | https://conductscience.org/library/papers/42920926 | PubMed |
| 42913630 | Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade. | Cell | 2026 | https://conductscience.org/library/papers/42913630 | PubMed |
| 42897893 | Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/42897893 | PubMed |
| 42866251 | Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade. | iScience | 2026 | https://conductscience.org/library/papers/42866251 | PubMed |
| 42854695 | Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42854695 | PubMed |
| 42833860 | Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42833860 | PubMed |
| 42797500 | Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797500 | PubMed |
| 42795023 | Management of Melanoma in Advanced Age: A Comprehensive Literature Review of Tumor Biology, Systemic Therapies and Geriatric Challenges. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42795023 | PubMed |
| 42750158 | Spatiotemporally Controlled Sequential Chemo-Immunotherapy Activates Pyroptosis for Robust Anti-Tumor Immunotherapy. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42750158 | PubMed |
| 42738322 | From Pixels to Stroma: AI-Driven Spatial Profiling of Cancer-Associated Fibroblasts on H&E and Its Implications for Immunotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738322 | PubMed |
| 42729917 | Immune checkpoint inhibitor treatment - real-world use and outcomes in Sweden 2015-2023. | Ups J Med Sci | 2026 | https://conductscience.org/library/papers/42729917 | PubMed |
| 42705865 | Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42705865 | PubMed |
| 42699924 | Primary gastric melanoma in an Asian patient: a rare case report of early detection and therapeutic uncertainty. | Int J Surg Case Rep | 2026 | https://conductscience.org/library/papers/42699924 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| CXCL10 | 3627 | PubTator's text mining | https://conductscience.org/library/genes/3627 | NCBI Gene |
| CXCL9 | 4283 | PubTator's text mining | https://conductscience.org/library/genes/4283 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| IPILIMUMAB | CHEMBL1789844 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1789844 | ChEMBL |
| NIVOLUMAB | CHEMBL2108738 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108738 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28889792
GET https://conductscience.org/api/papers/v1/28889792/authors?page=2